Tyzeka(TM) Receives US Regulatory Approval As A New Treatment For Patients With Chronic Hepatitis B

Thu, 02 Nov 2006 02:00 PM EST

... Novartis announced today the US regulatory approval of Tyzeka(TM) (telbivudine) as a new once-a-day oral treatment for patients with chronic hepatitis B, a disease estimated to affect about 1.25 million people in the US but more than 350 million globally and considered the tenth leading cause of death. [click link for full article] ...